[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352210-105":59,"doc-detail-352210-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gpr143-a-novel-immunohistochemical-marker-for-renal-tumors-with-flcntscmtor-tfe-alterations","GPR143, a novel immunohistochemical marker for renal tumors with FLCN/TSC/MTOR-TFE alterations","","Diagnosis of microphthalmia (MiT)/TFE family translocation renal cell carcinoma can be difficult because tumor morphology overlaps and reliable biomarkers are limited. GPNMB has been proposed as a diagnostic immunomarker for renal neoplasms with FLCN/TSC/mTOR-TFE alterations, but sensitivity and specificity remain suboptimal and ambiguous cases are hard to interpret. Bioinformatic analyses identified GPR143 as highly expressed in a subset of renal cell carcinomas, enriched for FLCN/TSC/mTOR-TFE alterations. Immunohistochemistry showed GPR143 positivity in most tRCC cases and in renal tumors with FLCN/TSC/mTOR alterations, with occasional discordance versus GPNMB. Results support GPR143 as an adjunct marker to improve screening sensitivity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gpr143-a-novel-immunohistochemical-marker-for-renal-tumors-with-flcntscmtor-tfe-alterations/352210/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gpr143-a-novel-immunohistochemical-marker-for-renal-tumors-with-flcntscmtor-tfe-alterations/352210.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is diagnosing MiT/TFE family translocation renal cell carcinoma challenging?","Question",{"text":112,"@type":113},"It is challenging due to diverse and overlapping tumor morphology and the lack of reliable biomarkers, which complicates accurate interpretation in routine practice.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is GPR143, and how is it related to FLCN/TSC/mTOR-TFE alterations?",{"text":117,"@type":113},"GPR143 is a transmembrane protein regulated by MiT transcription factors. In TCGA cohorts, high GPR143 expression was enriched in renal neoplasms carrying FLCN/TSC/mTOR-TFE pathway alterations, and IHC supported its diagnostic surrogate value in a subset of tumors.",{"name":119,"@type":110,"acceptedAnswer":120},"How do GPR143 and GPNMB immunostaining results compare?",{"text":121,"@type":113},"They were concordant in most renal neoplasms with FLCN/TSC/mTOR-TFE alterations, but some cases showed diffuse GPR143 staining despite negative or focal GPNMB labeling, indicating potential added sensitivity with GPR143 as an adjunct marker.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352210,1790814673,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Virchows Archiv (2026) 489:619–630  \n[https://doi.org/10.1007/s00428-026-04646-4](https://doi.org/10.1007/s00428-026-04646-4)  \nORIGINAL ARTICLE  \nGPR143, a novel immunohistochemical marker for renal tumors with FLCN/TSC/MTOR-TFE alterations  \nQinyuan Li1 · Anupama Singh1 · Rong Hu1 · Wei Huang1 · Daniel D. Shapiro2 · E. Jason Abel2 · Yang Zong1  \nReceived: 5 March 2026 / Revised: 22 June 2026 / Accepted: 10 July 2026 / Published online: 17 July 2026 © The Author(s) 2026  \nAbstract  \nAlthough several ancillary tests are available in limited laboratories, diagnosis of microphthalmia (MiT)/TFE family translocation renal cell carcinoma (tRCC) could be challenging due to diverse and overlapping tumor morphology and the lack of reliable biomarkers. GPNMB has been recently identified as a diagnostic marker for various renal neoplasms with FLCN/TSC/mTOR-TFE alterations. However, the sensitivity and specificity of GPNMB immunostain are suboptimal and the result interpretation in ambiguous cases could be difficult. To search additional biomarkers that could improve the screening sensitivity and predict genetic aberrations in FLCN/TSC/mTOR-TFE pathway in renal tumors, we performed bioinformatic analysis of publicly available cancer databases and found GPR143, a transmembrane protein regulated by MiT transcription factors, was highly expressed in a subset of renal cell carcinomas (RCCs) . In two kidney cancer cohorts of the Cancer Genome Atlas (TCGA), RCCs with high levels of GPR143 expression were enriched for renal neoplasms with FLCN/TSC/mTOR-TFE alterations. Similar to GPNMB labeling, GPR143 immunostain was positive in the majority of tRCC cases and renal tumors with FLCN/TSC/mTOR alterations, suggesting that GPR143 could function as another surrogate marker for FLCN/TSC/mTOR-TFE alterations in certain renal tumors. Interestingly, despite the concordant GPR143 and GPNMB immunoreactivity in most renal neoplasms with FLCN/TSC/mTOR-TFE alterations, diffuse GPR143 immunostain was observed in some cases with negative or focal GPNMB labeling. Taken together, our results indicate GPR143 could serve as a useful adjunct marker to improve the sensitivity for screening renal tumors with FLCN/ TSC/mTOR-TFE alterations.  \nKeywords Renal cell carcinoma · TFE · Translocation · GPR143 · GPNMB  \nIntroduction  \nGPNMB (Glycoprotein nonmetastatic melanoma protein B), a transmembrane protein regulated by the microphthalmia (MiT)/TFE family of transcription factors, has been recently discovered as a diagnostic biomarker for various renal neoplasms with FLCN/TSC/mTOR-TFE alterations [1, 2] . High expression of GPNMB was found in MiT/TFE family translocation renal cell carcinoma (tRCC) [1–3],  \n Yang Zong[zong25@wisc.edu](zong25@wisc.edu)  \n1 Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of WisconsinMadison, 600 Highland Avenue, Madison, WI 53792, USA  \n2 Department of Urology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison,WI, USA  \nrenal tumors associated with Birt–Hogg–Dubé (BHD) syndrome or somatic FLCN mutations [4–6], and many renal tumors associated with TSC/mTOR signal pathway aberrations, including renal cell carcinoma (RCC) with fibromyomatous stroma, [7–9] eosinophilic solid and cystic renal cell carcinoma (ESC RCC), low grade oncocytic tumor (LOT) and eosinophilic vacuolated tumor (EVT) [1, 2, 6] as well as angiomyolipoma [1, 2] . However, approximately 13%—30% of tRCC cases are negative for diffuse GPNMB staining [1, 2] . Furthermore, a large fraction of chromophobe renal cell carcinoma (chRCC) show diffuse or partial positive immunoreactivity with GPNMB antibody [1, 2, 6] . Several other renal epithelial tumors including oncocytoma, clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) could rarely exhibit diffuse or focal staining for GPNMB [2, 5, 6] .  \nGiven that many renal neoplasms with FLCN/TSC/ mTOR-TFE alterations also expres","cbCaisiv50nFjKOO","https://ap.wps.com/l/cbCaisiv50nFjKOO","pdf",5121484,12,"English","# Abstract\n## Introduction\n## Materials and methods\n### Bioinformatics tool and data analysis","[{\"question\":\"Why is diagnosing MiT/TFE family translocation renal cell carcinoma challenging?\",\"answer\":\"It is challenging due to diverse and overlapping tumor morphology and the lack of reliable biomarkers, which complicates accurate interpretation in routine practice.\"},{\"question\":\"What is GPR143, and how is it related to FLCN/TSC/mTOR-TFE alterations?\",\"answer\":\"GPR143 is a transmembrane protein regulated by MiT transcription factors. In TCGA cohorts, high GPR143 expression was enriched in renal neoplasms carrying FLCN/TSC/mTOR-TFE pathway alterations, and IHC supported its diagnostic surrogate value in a subset of tumors.\"},{\"question\":\"How do GPR143 and GPNMB immunostaining results compare?\",\"answer\":\"They were concordant in most renal neoplasms with FLCN/TSC/mTOR-TFE alterations, but some cases showed diffuse GPR143 staining despite negative or focal GPNMB labeling, indicating potential added sensitivity with GPR143 as an adjunct marker.\"}]","GPR143, a novel immunohistochemical marker for renal tumors with FLCN/TSC/MTOR-TFE alterations | PDF",1790098305,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f873e96c90aa0c8c206cce0caad918a.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86d17f32ccc62477122ba44b00c37426.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e77d7f6cf6d93520b0d6bad4186486af.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73fee43bfeaf2ddef190b41daa638fd4.webp",980,1301]